Traditionally, the THC content is the sole indicator of strength and quality of a variety, but that's changing, while the benefits of the other cannabinoids, and in particular the CBD are scientifically recognized. THC is the cannabinoid that is largely responsible for the psychoactive effects of cannabis and is at recreational users because of its intoxicating properties still the most sought-after connection. For this reason, most breeders have focused on increasing the THC content, but neglected other cannabinoids such as CBD.
With more and more scientific evidence supporting the medicinal effects of cannabis, we see not only a revival of the legal and socially acceptable use of medical cannabis, but also a shift of focus to other cannabinoids. THC has proved that it has its own medicinal qualities, but it is the CBD, which has moved because of its wide range of medical qualities into the spotlight. Especially the lack of a psychoactive effect makes CBD attractive for a variety of applications because it was administered successfully children without it caused a frenzy. As a result, produce cannabis breeders now many new varieties that have high CBD values.
While the mass media CBD pick up on stories of how the little girl Charlotte, who beat her epilepsy with a CBD-rich variety, the consciousness spread all over the potent medicinal qualities of this cannabinoid. The legalization of cannabis for medical and recreational use in a number of U.S. states has the availability of CBD-rich varieties increased even further. However, not all medical users lucky enough to be able to buy cannabis in pharmacies legal and illegal cannabis from the road is not suitable for medical use. Therefore, many take it into their own hands and build their own supply, from which they produce their own drugs such as tinctures and concentrates.
CBD is the abbreviation for cannabidiol, the second most important after the THC and cannabinoid in the cannabis plant. If you look at the cannabinoid content of a variety, it is quite common to find a THC content of about 12-20 percent, where everything is 20 or more, as is very highly regarded. This is not the case in the CBD - it is rare that such high values of it are to be found; each CBD content, which is 4 percent or more is regarded as a CBD-rich species. Although 1% CBD is already much better than nothing, but in recent years, varieties with 18% CBD have emerged, although they are still rather difficult to come by. Commercially available CBD-rich varieties contain between 8-12% CBD.
WHAT CAUSES CBD?
Initially it was always thought that CBD would modulate and attenuate some of the effects of THC - which was a good reason for growers to neglect it. Recent studies have shown, however, that it is actually the CBD, which potentially has the most medicinal value. It is true that CBD changed the way how THC interacts with our body, but not necessarily negative. It counteracts some of the unwanted side effects that may be associated with high THC doses, and prolong its effects.
Used alone, it has been shown in the CBD that it is applicable and useful in a variety of diseases, ailments and problems. Research has shown that CBD showed promising results in the treatment of multiple sclerosis, Crohn's disease, Alzheimer's disease,Parkinson's disease, PTSD,and epilepsy, CBD is a component of cannabis that may help the patient to cope with chronic pain, cramps, and arthritis.
Again, it should be noted that CBD, unlike THC, is not psychoactive. Therefore, and tinctures and extracts are used to treat children suffering from debilitating illnesses - such as the above-mentioned case of Charlotte, a cannabis takes tincture, which is made from the aptly called CBD-rich variety "Charlotte's Web", to fight their seizures. Before taking cannabis Charlotte had 1,200 seizures per month - now she has about 3 and shows a balanced behavior.
In addition, CBD has no negative side effects, does not harm the body or mind, is not addictive and can not be overdosed
THE TOP 5 OF THE CBD-RICH VARIETIES
The following 5 varieties are those who have shown that they have a very high CBD content and are well suited for those who want to establish and / or grow their own medicine. You are highly recommended.
CBD Crew Shark Shock Shark Shock is one of the fine creations of the breeder of the CBD crew. The CBD crew are cannabis growers who defy the norm. They are not interested in mass-market THC-rich varieties and focus all their energy on CBD-rich, high-quality, medical varieties. Shark Shock is no exception, it is one of the few species where the CBD content outweighs that of THC. With an average THC content of 6.33% and a CBD content of as much as 7.28%, it is a perfect strain for medical users.
If you decide you to vaporize it (smoking is never really recommended), Shark Shock produces a sweet, fruity steam. Since their origin is mainly dominated by Indica, Shark Shock grows with small stature, has a short flowering period of about 8 weeks and can bring in close to 400g / m². She is a tough little plant and an enrichment in the collection of any medical breeder.
The result of a joint venture of the CBD crew and the breeder of Dutch CBD - Skunkhaze is a great medical advancement of a classic variety. CBD Skunkhaze was definitely grown oriented on the medical users. This variety was bred to the desirable 1:1 ratio of THC: CBD to achieve, with 5% THC and 5% CBD came out. The result is a gentle and pleasant anesthetic, but more importantly, a potent medicine to combat the many ailments that CBD absorbs's grain.
CBD Skunkhaze simultaneously produces a spicy, fresh, lemony and minty steam. As the name suggests, CBD Skunkhaze a 50/50 Sativa / Indica hybrid. It is big, but not overwhelming and has a flowering time of about 10 weeks. You can produce income in the range of 450g / m².
Royal Highness is Royal Queen Seeds' response to medical varieties. Although the specific THC and CBD levels are not known, both are given by the breeder to be very high - and both we here at Zamnesia, as well as medical patients agree. It creates a frenzy, in which the head remains very clear and focused, while the treated complaints are effectively addressed.
If it is vaporized, Royal Highness has a pronounced sweet taste that has skunkige undertones. There is another variety that is easy to handle for beginners in the cultivation itself. It grows like an indica, small and sturdy in stature and has a flowering time of about 8-9 weeks
And yet another variety that was created by the breeders of the CBD Crew - CBD Nordle that transcends the boundaries of the CBD to the next level. It has a tested CBD content of at most 8.97 percent, with the THC content is at 6.43 percent. It is a work of art of breeding and a testament to the skills of the CBD crew. There are few varieties that would give finer Medicine; the focus in this grade is the treatment, not waiting to be high. You'll hardly find a variety with higher CBD content (even if we are sure that we will succeed the CBD team).
If it is vaporized, CBD Nordle has a very strong and herbaceous taste. She is a very beginner-friendly plant that grows with small stature, in a form similar to a Christmas tree. CBD Nordle is dominated by Indica hybrid that blooms around the 8-10 weeks and can produce up to 500g / m².
CBD MEDICARE HAZE
CBD Medicare Haze is the latest creation of the CBD crew. It is dominated by a sativa strain that has been enriched with an insane CBD content. Tests have shown that the CBD can reach content in this strain up to 8 percent, with the THC content reaches only 4 percent! It is once again an amazing feat of breeding and perfect for medical patients.
If you CBD Medicare evaporate Haze, they will produce a spicy, minty taste. When dominated by Sativa variety, CBD Medicare Haze can grow quite high. After its heyday from 9-10 weeks, they can bring in an income of 450-550g / m².
Cannabis Research: Alzheimer’s Disease
Alzheimer’s is a physical disease of the brain and one of the most common causes of dementia. It causes the formation of “extracellular” and “fibrillar” deposits, which means that cells die in the brain. This progressive disorder causes slowly more and more brain damage, in which the mental condition of the patient gradually deteriorated. The symptoms of Alzheimer’s disease are:
Memory Loss – Is easily confused and finds it difficult to remember names, places, people and recent events.
Mood swings – Can easily be angry, anxious or frustrated as a result of increasing memory loss.
Withdrawal – Pulls emotionally still further back, the more difficult the communication.
Cannabis & Alzheimer’s studies:
1) prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection by blockade of microglial activation (Prevention of Alzheimer’s Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation – 2005)
Cannabinoids are known to act as neuroprotective agents in the brain. This prompted the researchers, the function of the cannabinoid receptors and the possible protective properties that have the cannabinoids in marijuana to judge in Alzheimer’s patients. They found that the cannabinoid receptors play a role in the illness and that prevent the cannabinoids that the neurodegenerative process is taking place. Published in the “Journal of Neuroscience.”
2) Marijuana slows decay by Alzheimer’s disease (Marijuana Slows Alzheimer’s Decline – 2005)
Studies of the Hebrew University in Jerusalem, who were eye aimed to find out whether the non-psychedelic cannabinoids in cannabis may help in the treatment of Alzheimer’s disease. They found positive results in mice, which indicated that the use of cannabis could slow down the degeneration of memory. Published by the “Israel National News”.
3) A molecular link between the active component of marijuana and Alzheimer’s disease pathology (A Molecular Link Between The Active Component of Marijuana and Alzheimer’s Disease Pathology – 2006)
This research aimed to find out what role THC, in contrast to the non-psychoactive cannabinoids, could play in the treatment of Alzheimer’s disease. It has been found that THC inhibits effectively the AB Group, the principal pathological markers of Alzheimer’s disease. They took together that the effect that had THC, was even better than that of prescription drugs that were at the time available. Published in “Molecular Pharmaceuticals.”
Cancer is a large group of diseases, which results in uncontrolled and rapid cell growth. Due to the uncontrolled growth of the cancer cells invade the surrounding healthy tissue and destroy it. Cancer usually starts in one part of the body, but can spread through the bloodstream and lymphatic system. There are more than 200 types of cancer that occur in humans, which all have different symptoms, depending on where they are located.
Brain cancer studies:
1) Anti-tumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines (anti-tumor effects of cannabidiol, a cannabinoid Nonpsychoactive, on Human Glioma Cell Lines - 2003)
Under laboratory conditions, research has been conducted in order to investigate the hypothesis that CBD have anti-tumor properties. It was found that CBD is the viability of the tumor cells dropped significantly, suggesting that CBD is an effective antitumor agent. Published in the "Journal of Pharmacology and Experimental Therapeutics."
2) Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain induced by excitotoxicity in the living organism (Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo excitotoxicity - 2001)
This research was designed to investigate the effects of THC on acute brain damage and brain degenerative diseases. It has been found that THC has an effect that protects the brain from degenerative diseases. Published in the "Journal of Neuroscience."
3) A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme - 2006)
This study was the first that was designed to explore the antitumor properties of cannabinoids in a clinical setting. She came to positive results, and it was found that THC and other cannabinoids inhibit tumor growth in patients. Published in the "British Journal of Cancer."
4) A combined preclinical therapy of cannabinoids and temozolomide against glioma (A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma - 2011)
This research aimed to evaluate the use of THC in conjunction with the drug TMZ in the treatment of glioblastoma multiforme - the most common and very resistant form of brain cancer. It has been found that the combined treatment showed that the reversed-tumor activity. Published in the journal "Molecular Cancer Therapeutics."
Breast cancer studies:
1) Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma - 2006)
This research recognizes the antitumor effects of THC, but claims that it was problematic because of its psychoactive properties. Therefore, they went on to assess the effects of other cannabinoids. It was found that CBD showed promising anticarcinogenic characteristics that should be investigated further. Published in the "Journal of Pharmacology and Experimental Therapeutics."
2) pathways in mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion and metastasis (Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis - 2010)
This study was designed to determine the effects of CBD on breast cancer cells. It was found that it inhibited the growth and the spread of these cancer cells. It has also been discovered that CBD significantly reduced the tumor mass. Published in the "U.S. Library of Medicine."
3) Cannabinoids reduce ErbB2-driven breast cancer progression through AKT inhibition (Cannabinoids reduce ErbB2-driven breast cancer progression through AKT inhibition - 2010)
This research describes experiments that were performed to assess the effects of cannabinoids on the very aggressive ERB2-positive breast cancer. They concluded that cannabinoids both tumor growth, as well as the amount of existing tumors appeared to decrease, which strongly suggests that they represent a real application for the therapeutic treatment of breast cancer. Published in the journal "Molecular Cancer."
4) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation (The endogenous cannabinoid anandamide Inhibits human breast cancer cell proliferation - 1998)
This research was designed to investigate the effects of cannabinoids on the proliferation of breast cancer cells. It has been found to inhibit the growth. Published in the "National Academy of Sciences (PNAS)."
Lung cancer studies:
1) Δ9-Tetrahydrocannabinol inhibits both triggered by the epithelial growth factor lung cancer cell migration outside of the living organism, as well as the growth and metastasis in the living organism (Δ9-Tetrahydrocannabinol Inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo - 2008)
This research was conducted to study the effects of THC to the epithelial growth factor induced by cancer - a particularly aggressive and resistant to chemotherapy form of cancer. It was found that THC has played a significant role in inhibiting cancer growth, which justifies further research in this direction. Published in the journal "Oncogene."
2) Cannabidiol inhibits lung cancer cell invasion and metastasis via the intercellular adhesion molecule-1 (Cannabidiol Inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1-2011)
In this research, it was tried to examine the effects of CBD on the invasiveness of cancer. It has been found that cannabinoids inhibit the invasiveness of the primary tumor cells in patients with lung cancer. Published in the "U.S. National Library of Medicine."
3) The cannabinoid receptors CB1 and CB2 as new targets for the inhibition of large cell lung cancer growth and metastasis (cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis - 2011)
This research was conducted to determine the role of the cannabinoid receptor activation in lung cancer. It has been found that both inhibit the growth of cancer cells and enhance their apoptosis - the natural process of cell death. Published in the "U.S. National Library of Medicine."
Prostate cancer studies:
1) Anti-proliferative and apoptotic effects of anandamide in human Prostatakrebszellinien: implication of the reduction of epidermal growth factor receptors and ceramide production (anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production - 2003)
This study describes how the activation of cannabinoid receptors causes an antiproliferative effect in cancer cells in the prostate, which has major implications for the treatment of prostate cancer. Published in the "U.S. National Library of Medicine."
2) The role of cannabinoids in prostate cancer: basic scientific point of view and possible clinical applications (The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications - 2012)
This study conducted a multi-evaluation of many other previous research on prostate cancer to determine whether cannabinoids have a practical clinical application. It has been found that it is in everyone's best interest to conduct clinical trials of medical cannabis. Published in the "U.S. National Library of Medicine."
3) Non-THC Cannabinoids inhibit prostate cancer growth in vitro and in vivo: Pro-apoptotic effects and the underlying mechanisms (non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms - 2013)
This research was designed to extend the previously explored idea that cannabinoid receptor activation causes cell death in prostate cancer cells. The research found significant positive results and found that the data supported the clinical tests of CBD from prostate cancer patients. Published in the "U.S. National Library of Medicine."
Blood cancer studies:
1) cannabinoid receptor-mediated apoptosis induced by R (+)-methanandamide and WIN55 0.212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma (Cannabinoid Receptor-Mediated Apoptosis Induced by R (+)-Methanandamide and WIN55, 212 - 2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma - 2006)
This research was designed to explore whether cannabinoids inhibit cancer cells in lymphomas. It describes that it has been found that cannabinoids inhibit the growth and induce cell death in mantle cell lymphoma (blood cancer). Published in the journal "Molecular Pharmacology."
2) triggered by Δ9-tetrahydrocannabinol apoptosis in Jurkat T-leukemia cells is regulated by the translocation of BAD mitochondria. (Δ9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria - 2006)
This research discusses how the use of cannabinoids in apoptosis (regulated and the natural death of cells) is to be evaluated. They yielded positive results, and it was found that cannabinoids actually cause the death of carcinogenic leukemia cells. Published in the "U.S. National Library of Medicine."
3) Activation of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation (expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation - 2008)
This research aimed to determine the effects of the cannabinoid receptor activation on lymphomas. It has been found that the cannabinoid receptor activation, the multiplication and growth of lymphoma reduced, and causes the death of some cancer cells. Published in "International Journal of Cancer."
Oral cancer studies:
Cannabinoids inhibit cellular respiration of human oral cancer cells (Cannabinoids inhibit cellular respiration of human oral cancer cells - 2010)
This research was aimed to investigate the effects of cannabinoids on cell respiration in certain types of oral cancer. It has been found that cannabinoids inhibit cancer cell respiration and therefore have a toxic effect on them. This implies that cannabinoids may be used for the treatment of oral cancer. Published in the "U.S. National Library of Medicine."
Liver cancer studies:
Anti-tumor effect of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy (Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy - 2011)
This research aimed to determine what the effects of THC on cancer cells in the liver. It has been found that the growth of THC and the effectiveness of these cancer cells is reduced, which means that THC should be further examined as a therapeutic treatment. Published in the "U.S. National Library of Medicine."
Pancreatic cancer studies:
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes (Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes - 2006)
This study suggests that pancreatic tumor tissue seems to have a much higher number of cannabinoid receptors compared to normal pancreatic tissues. The study found that, when the cannabinoids are administered to cancer cells began to die by apoptosis, resulting in a reduction in the growth and spread of the tumor. Published in "The American Journal of Cancer."
Chronic pain is pain that persists for more than 6 months. They are often a symptom of an underlying disease, such as cancer and multiple sclerosis, but can also be caused by a simple injury or infection. Chronic pain can take many forms, be it mild or excruciating and has in those affected usually a slow emotional impact. Prescribed drugs can often be ineffective or have undesirable side effects, so the effect of cannabis has been explored as a pain reliever.
Studies in this area:
1) Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, clinical cross-over study (Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial - 2008)
This study was conducted to determine how effectively acts cannabis in the treatment of chronic pain caused by nerve, caused by HIV. Here it was found that participants reported with the use of cannabis from a better pain relief than those who were given a placebo and that it was most effective when it was used in conjunction with other pain relieving therapies. Published in the journal "Neuropsychopharmacology."
2) Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia by in healthy volunteers (Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers - 2007)
Researchers conducted this study to examine how smoking cannabis would affect the perception of pain in patients induced with capsaicin pain suffered (the compound in chili peppers that causes a burning sensation when it comes in contact with tissue). They found that those who smoked a mean dose reported a significant reduction in pain, while those who smoked a higher dose, reported a significant increase in the induced pain. Published in the journal "Anesthesiology."
3) cannabinoids for the treatment of chronic pain that is not caused by tumors, a systematic review of randomized trials. (Cannabinoids for treatment of chronic non-cancer pain, a systematic review of randomized trials - 2011)
This study aimed to demonstrate the limited options that are available for those who suffer from chronic pain. They introduced random studies that compared the cannabis with a placebo and their effect on pain. It has been found that the use, cannabis, compared to those with a placebo, reported a significant pain reduction. Moreover, it has been found that the use of triggered no serious side effects. In summary, it was found that cannabinoids appear to be an effective and safe way to treat pain. Published in the "U.S. National Library of Medicine."
Cannabis Research: Diabetes
Diabetes mellitus is a group of diseases that is most commonly associated with a lack of insulin production, causing the blood sugar level is regulated wrong. There are two main types of diabetes, type 1 diabetes and type 2 diabetes. Patients who suffer from Type 1 diabetes, can ever produce no own natural insulin and are dependent on medication to survive. Type 2 diabetes patients do not produce enough insulin to support their body. This is a less severe form and can often be controlled with a strict diet. Untreated diabetes can lead to kidney failure, blindness, amputations and death.
To this end, studies carried out:
1) Cannabinoids block tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. (Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect - 2004)
Caused by diabetes nerve pain is one of the most common causes of chronic pain. However, diabetics are less sensitive to the effects of analgesic drugs such as morphine and other opiates. This leaves the sufferer few options. This study was designed to assess the efficacy of cannabinoids in treating this type of pain. Through testing on diabetic mice found that cannabinoids may have a positive effect on pain reduction. Published in the "U.S. National Library of Medicine."
2) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice (cannabidiol Lowers incidence of diabetes in non-obese diabetic mice - 2006)
This study was aimed to find out whether the cannabinoid CBD has an effect on the rate of diabetes-prone mice occurs in type 1 diabetes. It has been found that the onset of diabetes from a baseline of 86% in an untreated group to 30% in a group of mice treated with CBD, decreased. Published in "IngentaConnect."
3) Neuroprotective and blood-retinal barrier protective effects of cannabidiol in experimental diabetes. (Neuroprotective and Blood-Retinal Barrier-Preserving Effects if cannabidiol in experimental Diabetes2006)
This study examines how the non-psychoactive cannabinoid CBD may be applied to reduce damage to the retina caused by diabetes. Here, it was found that CBD inflammation, neurotoxicity and blood-retina in diabetic animals reduced expiration, indicating that the drug may be used to prevent the diabetic retinopathy. Published in the "U.S. National Library of Medicine.
Cannabis Research: Epilepsy
Epilepsy is a neurological disorder that causes intense bursts of electrical energy within the brain. This causes a temporary but recurring disorder, how the brain works - which leads to an epileptic seizure. An epileptic seizure can, among many other symptoms, loss of consciousness, sensory disturbances and convulsions Run.
1) cannabidiol shows antiepileptiforme properties and counteracts Krämofen; in vitro and in vivo (cannabidiol displays Antipileptiform and antiseizure Properties In Vitro and In Vivo - 2010)
This research aimed to experimentally explore the wider effects of CBD on its anticonvulsant properties in animals and in isolated tissue. It was found that CBD and its effects on the CB1 receptors showed the potential to inhibit epileptiform activity in isolated tissue samples and to reduce the severity of seizures in living animals. Published in the "U.S. National Library of Medicine."
2) Cannabidivarin has an antispasmodic effect in mice and rats (Cannabidivarin is anticonvulsant in mouse and rats - 2012)
This research was aimed to test the effect of the cannabinoid CBDV for cramps, such as those caused by epilepsy. It has been found that the use of such a cannabinoid effectively prevented convulsions and appeared to have no adverse effects on normal functions. Published in the "British Journal of Pharmacology."
3) Marijuana, Endocannabinoids and epilepsy: potentials and challenges for an improved therapeutic intervention (Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention - 2013)
This research is a meta-study, which describes that the results of many other studies show apparently that cannabinoids and marijuana potentially beneficial for those act who suffer from neurological disorders such as epilepsy. Published in the "U.S. National Library of Medicine."
Cannabis Research: gastrointestinal disorders
A gastrointestinal disorder is a disorder in which the bowel appears normal, but is not functioning properly. Common examples of such a disorder are irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and constipation.
Studies in this area:
1) Cannabinoids and the gastrointestinal tract (gastrointestinal tract and the Cannabinoids - 2001)
This study aimed to evaluate the effect of cannabinoids on the digestive system. It was found that the activation of CB1 receptors in the endocannabinoid system inhibits the production of stomach acid, suggesting that it could be used by patients for whom too much is produced and who have irritable bowel symptoms. It has also been found that there appears to be no adverse effects or withdrawal symptoms were, which can be associated with the use of cannabinoids. Published in the journal "Good."
2) Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing (Differential Expression of Cannabinoid Receptors in the Human Colon: Cannabinoids Promote Epithelial Wound Healing - 2005)
In this study it was attempted to find the position of the cannabinoid receptors in the large intestine and to determine their function. It was found that the cannabinoid receptors are distributed throughout the colon to find and that they play a role in alleviating IBD. Published in the journal "Gastroenterology."
3) Endocannabinoids and the gastrointestinal tract (gastrointestinal tract and the endocannabinoid - 2006)
This research was designed to explore the historical use of cannabis as a medicine in the treatment of gastrointestinal problems and whether cannabis really has an effect. It was found that the endocannabinoid system serves to protect the Verdauuungssystem against anomalies, which means that cannabis may be an effective way to treat those who suffer from such diseases. Published in the "U.S. National Library of Medicine."
4) Cannabis use in patients with chronic inflammatory bowel disease (Cannabis use amongst patients with inflammatory bowel disease - 2011)
Previous studies suggest that the endocannabinoid system plays a role in preventing and protecting against inflammation in the colon. Through questionnaires, which assessed the habits of cannabis use of patients with related disorders, it was found that the use of cannabis seemed to have a positive therapeutic benefit and further research should be carried out in this direction. Published in the "U.S. National Library of Medicine."
Cannabis Research: HIV
Human Immunodeficiency Virus (HIV) is a retrovirus that attacks the human immune system and the acquired immunodeficiency syndrome (AIDS) triggers - a disease that sets the immune system slowly overridden, so that those who are suffering from increasingly vulnerable to life-threatening disease be.
1) Marijuana as therapy for people living with HIV / AIDS: Social and health aspects (Marijuana as therapy for people living with HIV / AIDS: Social and health aspects - 2007)
This research aimed to evaluate the therapeutic use of cannabis in HIV patients. It was found that used as part of their treatments despite the many legal barriers, many marijuana affected by HIV and thus achieve a positive therapeutic effect. Published in the journal "AIDS Care:. Psychological and Socio-medical Aspects of AIDS / HIV"
2) dronabinol and cannabis in HIV-positive marijuana smokers: caloric intake, mood, and sleep (Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep - 2007)
This study confirms the count affected by HIV to one of the largest groups of medical marijuana users, but testified that no studies have been conducted to compare the effectiveness of oral use in this situation. It was found that in comparison to a placebo group, the group smoked cannabis, increased food intake had and was not affected by the noise. Published in the "Journal of Acquired Immune Deficiency Syndrome."
3) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial (Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial - 2003)
This study describes that marijuana could possibly have an influence on the use of other HIV drugs. The aim of the study was to determine whether the use of marijuana has any negative effects. It was found that the short-term use of marijuana apparently had no effect on the spread of the virus from the participant, suggesting that marijuana caused no adverse effect in combination with other medicines. Published in the "Annals of Internal Medicine."